Maria Pennuto Principal Investigator Ricerca Oncologica Avanzata, Fisiopatologia e Rigenerazione Muscolare, Cervello e Sistema Nervoso
Marco Sandri Principal Investigator Ricerca Oncologica Avanzata, Fisiopatologia e Rigenerazione Muscolare
Luca Scorrano Principal Investigator Ricerca Oncologica Avanzata, Fisiopatologia e Rigenerazione Muscolare, Cervello e Sistema Nervoso
Carlo Viscomi Principal Investigator Ricerca Oncologica Avanzata, Fisiopatologia e Rigenerazione Muscolare, Cervello e Sistema Nervoso
Gene Expression, Non-Coding RNA, and Circular RNA Alterations in Patients with T-Prolymphocytic Leukemia. 2026 - Cancers (Basel) Gian Pietro Semenzato Clinico Ricerca Oncologica Avanzata
DLBCL-microenvironment interactions: cytokine profiling and ECM-mediated ibrutinib resistance in a 3D bone-based model. 2026 - Med Oncol. Francesco Piazza Clinico Ricerca Oncologica Avanzata
Estimated Oral Semaglutide Exposure Has Distinct Relationships With Glycaemic Response, Weight Loss and Gastrointestinal Tolerability. 2026 - Diabetes Obes Metab. Gian Paolo Fadini Clinico Ricerca Oncologica Avanzata
Multi-omic single nuclei profiling of murine pancreas shows dynamic epigenetic heterogeneity of acinar cells. 2026 - Cell Death Differ. Alessandro Carrer Principal Investigator Ricerca Oncologica Avanzata
Change in Effectiveness and Safety Parameters After Initiation of SGLT2 Inhibitors for Post-Transplant Diabetes Mellitus: A Real-World Observational Study. 2026 - Diabetes Ther Gian Paolo Fadini Clinico Ricerca Oncologica Avanzata
The importance of treatment sequencing with SGLT2 inhibitors and GLP-1 receptor agonists combination for kidney function preservation in type 2 diabetes. 2026 - Diabetes Obes Metab Gian Paolo Fadini Clinico Ricerca Oncologica Avanzata
Rethinking diabetes as a modifier of the weight-loss response to incretin-based therapies. A twin trial meta-regression. 2026 - Nutr Metab Cardiovasc Dis Gian Paolo Fadini Clinico Ricerca Oncologica Avanzata
The importance of treatment sequencing with SGLT2 inhibitors and GLP-1 receptor agonists combination for kidney function preservation in type 2 diabetes 2025 - Diabetes, Obesity and MetabolismDiabetes, Obesity and Metabolism Null Null Ricerca Oncologica Avanzata
Extent of bone marrow infiltration predicts disease progression in asymptomatic Waldenström macroglobulinemia. 2025 - Discover Oncology Francesco Piazza Clinico Ricerca Oncologica Avanzata
Reprogramming of cholesterol sensing in epithelial cells supports pancreatic inflammation. 2025 - Molecular Metabolism Alessandro Carrer Principal Investigator Ricerca Oncologica Avanzata
Resting-state functional connectivity guides motor hotspot localization. 2025 - Blood Advances Gian Pietro Semenzato Clinico Ricerca Oncologica Avanzata
Stratifying cardiovascular benefits from GLP-1RA: a multisource analysis of patient-level CVOT and real-world data using AI-driven methods. 2025 - Cardiovasc Diabetol Gian Paolo Fadini Clinico Ricerca Oncologica Avanzata
Type 2 diabetes remission after initiation of GLP-1 receptor agonists: frequency, characteristics, and outcomes using multiple definitions in an observational study 2025 - The Lancet Regional Health - Europe Gian Paolo Fadini Clinico Ricerca Oncologica Avanzata
Can Dual Incretin Receptor Agonists Exert Better Cardiovascular Protection than Selective GLP-1 Receptor Agonists? Highlights from SURPASS-CVOT 2025 - Diabetes Therapy Gian Paolo Fadini Clinico Ricerca Oncologica Avanzata
Effectiveness of oral semaglutide versus empagliflozin for the management of type 2 diabetes. PIONEER-2 trial emulation with real-world data. 2025 - Diabetes Obes Metab. Gian Paolo Fadini Clinico Ricerca Oncologica Avanzata
Incretins and the cardiovascular system: bridging digestion with metabolism 2025 - The Lancet Diabetes & Endocrinology | Journal Gian Paolo Fadini Clinico Ricerca Oncologica Avanzata
